Loading organizations...
Loading organizations...
BTG Limited was an international healthcare company that developed and commercialized specialty pharmaceuticals and interventional medicine. It offered innovative products for critical care, cancer, and other medical disorders. Its capabilities covered product development, manufacturing, and global commercialization, alongside strategic licensing of foundational technologies like magnetic resonance imaging.
BTG originated in 1981 as the British Technology Group, formed by the UK government to commercialize publicly funded research. A management buy-out from the government in 1992 led to its 1995 listing on the London Stock Exchange, adopting the name BTG Limited in 1998.
BTG Limited's products served physicians globally, treating patients across therapeutic areas including critical care and oncology. The company’s vision centered on advancing patient care through relentless medical innovation, equipping professionals with advanced interventional medicine and specialized pharmaceuticals to improve outcomes and patient quality of life.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 25, 2010 | Xention | $12.6M Series D | Graham Fagg | Credit Agricole Private Equity, Forbion, MVM Partners |